Radiation therapy for prostate cancer: can a blood test predict side effects?
Part of Cancer, Kidney & urinary clinical trials.
This study looks at whether a blood test can predict severe late side effects from radiation therapy for prostate cancer. The goal is to find out who might be at higher risk, so doctors can better plan treatment and reduce discomfort.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 60 or older.
- You have localized prostate cancer that is low or intermediate risk (meaning it hasn't spread and is not considered high risk).
- You have not had any surgery on your prostate or digestive system in the past.
- You are covered by the French national health system and can speak and understand French.
- You are willing to give written consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with prostate cancer who receive radiation to understand what side effects and quality-of-life changes happen over time. It may help improve standard follow-up care by better tracking radiation-related toxicity.
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
This trial compares two types of radiation therapy (SBRT and LDR brachytherapy) for men with low-risk or favorable intermediate-risk prostate cancer. The goal is to see which treatment causes fewer side effects.
This trial tests whether adding hormone therapy (ADT) to stereotactic body radiation therapy (SBRT) works better than SBRT alone for men with a specific type of prostate cancer called 'unfavorable intermediate risk.' The goal is to see if the combination helps control the cancer better.
This trial studies blood tests (liquid biopsies) in men with metastatic prostate cancer that no longer responds to hormone therapy or chemotherapy and who are receiving a type of radiation therapy called PSMA RLT. The goal is to see if these blood tests can provide useful information about the cancer and treatment response.
This study tests a tailored (personalized) radiation plan for men whose PSA (“prostate blood test”) rises after prostate surgery but who have no detectable spread on scans. It may help control cancer growth by targeting the right area based on your situation.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.